Home Journals Articles Updates About
CN
image
收藏切换
Global approved new drugs in 2022: retrospect and prospect
收藏切换
PDF
Hang-li HAN1, You-song SUN2, Qian CHEN3, Zhen-zheng YANG4, Xiao-nan ZHENG4
Chinese Journal of New Drugs | 2023, 32(18) : 1801 - 1808
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(18): 1801-1808
Global approved new drugs in 2022: retrospect and prospect
Full
Hang-li HAN1, You-song SUN2, Qian CHEN3, Zhen-zheng YANG4, Xiao-nan ZHENG4
Affiliations
  • 1School of Science, China Pharmaceutical University, Nanjing 210009, China
  • 2Shanghai Pharmadigger Technology Co., Ltd., Shanghai 201210, China
  • 33D Medicines Inc., Shanghai 200126, China
  • 4Editorial Office of Progress in Pharmaceutical Sciences, China Pharmaceutical University, Nanjing 210009, China
Published: 2023-09-30
Outline
收藏切换

In 2022, the heat index of the whole biomedical industry gradually declined, but the hot track such as gene therapy and cell therapy remains active. Source technology breakthroughs and multidisciplinary cross-integration innovation have accelerated the process of new drug development. There are a rich variety of new drugs approved in 2022, and some blockbuster new drugs and new technology therapies have brought new therapeutic hope for complex diseases. The Center for Drug Evaluation and Research (CDER) of the US FDA approved 37 innovative drugs in 2022, 25 of which were first approved worldwide. The European EMA approved 51 innovative medicines throughout the year, 8 of which were first approved worldwide. Japan's Pharmaceutical and Medical Device Agency (PMDA) approved 48 new drugs throughout the year, 12 of which were first approved in the world. The National Medical Products Administration (NMPA) of China approved 40 new drugs throughout the year, 11 of which were first approved worldwide. This paper summarized the new drugs approved for market in the US, EU, Japan and China in 2022, and provided an outlook on new drug development and biopharmaceutical development trends in 2023.

original new drug  /  first approval  /  cell and gene therapy  /  orphan drug
Hang-li HAN, You-song SUN, Qian CHEN, Zhen-zheng YANG, Xiao-nan ZHENG. Global approved new drugs in 2022: retrospect and prospect[J]. Chinese Journal of New Drugs, 2023 , 32 (18) : 1801 -1808 .
Appendix
Less
Year 2023 volume 32 Issue 18
PDF
32
11
Cite this Article
BibTeX
Article Info
  • Online Date：2026-03-05
  • Published：2023-09-30
Article Data
Affiliations
History
  • Accepted：2023-06-08
Affiliations
    1School of Science, China Pharmaceutical University, Nanjing 210009, China
    2Shanghai Pharmadigger Technology Co., Ltd., Shanghai 201210, China
    33D Medicines Inc., Shanghai 200126, China
    4Editorial Office of Progress in Pharmaceutical Sciences, China Pharmaceutical University, Nanjing 210009, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House